A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin

A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins) are associated with lower all-cause mortality than other anti-diabetic agents in patients with type 2 diabetes. In patients who may benefit from SGLT2is, but cannot add them to a dipeptidyl peptidase-4 inhibitor (DPP4i, glip...

Full description

Bibliographic Details
Main Authors: Chung-Huei Huang, Yu-Yao Huang, Brend Ray-Sea Hsu
Format: Article
Language:English
Published: King Faisal Specialist Hospital and Research Centre 2018-11-01
Series:Annals of Saudi Medicine
Online Access:https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2018.420

Similar Items

Similar Items